Evaluation of the Mutagenic Effect of Methanol Extract of Adiantum capillus-veneris Plant by Ames test

Document Type : Original Article


1 Student in Pharmacy, School of Pharmacy and Toxicology Research Center, Ahvaz, Iran.

2 Department of Pharmacology and Toxicology, School of Pharmacy and Toxicology Research Center, Ahvaz, Iran.

3 Student in Pharmacy, Student Research Committee, Ahvaz, Iran.

4 Department of Pharmacognosy, School of Pharmacy and Medicinal Plants and Natural Products Research, Ahvaz, Iran

5 Department of Microbiology, School of Medicine, Ahvaz, Iran


Background and Objective: Triterpenoids have been isolated from Adiantum capillus- veneris. These triterpenoids have antitumor effect. Their effect on DNA has been identified. Thus, the purpose of the present study was to obtain reliability of the non mutagenic effect of the methanolic Adiantum capillus-veneris extract using Amest test.
Subjects and Methods: Long maceration process (for 48 hrs) was carried out in order to extract all constitutes. Thin layer chromatography (TLC) method was used to evaluate aflatoxin B1 contamination and histidine amino acid presence. Minimum inhibitory concentration (MIC) was determined with dilution method. Salmonella typhimurium strain TA100 was used for determination of mutagenicity.  The genotype was confirmed by using histidine requirement, R- factor presence, rfa and uvrB mutations tests. The mutagenicity assay was performed at four extract concentrations (0.5, 1, 1.5 and 2mg/ml).  Sodium azide (NaN3) and methanol were used as the mutagens (positive control) and negative control, respectively in the absence or presence of liver-metabolizing enzymes.
Results: Adiantum capillus-veneris did have not significant mutagenic activity against negative control. The presence of liver-metabolizing enzymes did not exhibit a significant change on the number of colony formed. 
Conclusion: The results from this in vitro tests demonstrated that use of the extract fromAdiantum capillus-veneris plant in traditional medicine does not carry the risk of mutagenic or genomic changes.   


1-Deloi N, Khosravinia MR. [Culture of genetic engineering]. Tehran: National Center for Genetic Research and Biotechnology publication; 1994. [In Persian]
2-Esmith P, Hansel K. [Side effect of herbal drug]. Mashhad: Mashhad university publication; 1997. [In Persian]
3-Gardiner P, Kemper KJ, Legedza A, Phillips RS. Factors associated with herb and dietary supplement use by young adults in the United States. BMC Complement Altern Med 2007;7:39.
4-Ernst E. Systematic reviews of herbal medicines. Am J Med 2004;117:533.
5-Ayinehchiy Y. Materia of medical herbs and medicinal plants. Tehran: Tehran University Publication; 1991.  p.1035.
6-Ernst E. Risks of herbal medicinal products. Pharmacoepidemiol Drug Saf 2004;13(11):767-71.
7-Rietjens IM, Boersma MG, van der Woude H, Jeurissen SM, Schutte ME, Alink GM.  Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk. Mutat Res 2005;574(1-2):124–38.
8-Mei N, Guo L, Liu R, Fuscoe JC, Chen T. Gene expression changes induced  by the tumorigenic pyrrolizidine alkaloid riddelliine in liver of Big Blue rats. BMC Bioinformatics 2007;8Suppl7:S4.
9-Fu PP, Xia Q, Lin G, Chou MW. Pyrrolizidine alkaloids--genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 2004;36(1):1–55.
10-Montbriand MJ. Herbs or natural products that may cause cancer and harm part four of a four-part series. Oncol Nurs Forum 2005;32(1):E20-9.
11-Woo Y, Lai D, Arcos J, Argus M. Safrole, estragole and related compounds, In: Arcos JC, Argus MF, Woo Y, eds. Chemical Induction of Cancer. New York: Springer-Verlag; 1988. P. 267.
12- Birdsey MB. A brief description of the cycads. Fed Proc 1972;31:1467-9.
13-Louw WKA, Oelofsen W. Carcinogenic and neurotoxic component in the cycad Encephalartos altensteinii Lehm. (familyZamiaceae). Toxicon 1975;13:447–52.
14-Singh M, Singh N, Khare PB, Rawat AK. Antimicrobial activity of some important Adiantum species used traditionally in indigenous system of medicine. J Ethnopharmacol 2008;115(2):327–9.
15-Heber, PDR for herbal medicine. 3rd ed. London: Thomson publication; 2004. P. 542-3.
16-Imperato F. Sulphate esters of hydroxycinnamic acid-sugar derivatives from Adiantum capillus-veneris. Phytochemistry 1982;21:2717-8.
17-Abdel-Halim OB, Ibraheim ZZ, Shiojima K. Oleanane triterpenes from Adiantum capillus-veneris growing in Egypt. Alex J Pharm Sci 2002;16:87-92.
18-Jankowaski CK, Aumelas A, Thuery P, Reyes-Chilpa R, Jimenez-Estreda M, Barrios H, et al. X-ray,1H/13 C2D and 3D NMR studies of the structures of davallene and adipedatol, two triterpenes isolated from American Adiantum capillus-veneris. Polish J Chem 2004;78:389-408.
19-Guarrera PM, Lucchese F, Medori S. Ethnophytotherapeutical research in the high Molise region (central-southern Italy). J Ethnobiol Ethnomed 2008;4:7.
20-Zargari A. [Medical plants]. Tehran: Tehran University Publications; 1996. P. 513-38. [In Persian]
21-Hooper D. Useful plants and drugs of Iran and Iraq. Chicago: Field Museum Press; 1937. P. 115.
22-Abbasi AM, Khan  MA, Ahmad   M,  Zafar  M,  Khan  H, Muhammad N, et al. Medicinal plants used for the treatment of jaundice and hepatitis based on socio-economic documentation Afr J Biotechnol 2009;8(8):1643-50.
23-Besharat M, Rahimian  M, Besharat S, Ghaemi E. Antibacterial effects of Adiantum capillus-veneris ethanolic extract on three pathogenic bacteria in vitro. J Clin Diagn Res 2008;2:1242-3.
 24-Guha P, Mukhopadhyay R, Gupta K. Antifungal activity of the crude extracts and extracted phenols from gametophytes and sporophytes of two species of Adiantum. Taiwania 2005;50(4):272-83.
25-Victor B, Maridaas M, Ramesh U, Prabhu  JMA. Antibacterial activity of essential oils from the leaves of Adiantum capillus-veneris Linn. Malaysian J Sci 2003;22:65-6.
26-Gupta V, Bansal P, Kumar P, Kaur G. Anti-inflammatory and anti-nociceptive activity of Adiantum capillus. Res J Pharm Tech 2010;3:432-4.
27-Kumar A. Antioxidant effect of Adiantum capillus-veneris Linn. on human lymphocyte: an in vitro study. J Cell Tissue Res 2009;9:1899-902.
28-Purmorad  F, Hosseinimehr  SJ, Shahabimajd N. Antioxidant activity, phenol and flavonoid contents of some selected Iranian medicinal plants. Afr J Biothecnol 2006;5:1142-5.
29-Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 2002;99(1):326–35.
30-Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Jackson CE, et al. The synthetic triterpenoid2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res 2004;64(21):7927–35.
31-Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 2003;9(7):2798–806.
32-Ito Y, Pandey P, Sporn MB, Datta R, Kharbanda S, Kufe D. The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. Mol Pharmacol 2001;59(5):1094–9.
33-Hail N Jr, Konopleva M, Sporn M, Lotan R, Andreeff M. Evidence supporting a role for calcium in apoptosis induction by the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9- dien-28-oic acid (CDDO). J Biol Chem 2004;279(12):11179–87.
34-Hyer ML, Shi R, Krajewska M, Meyer C, Lebedeva IV, Fisher PB,  et al. Apoptotic activity and mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer. Cancer Res 2008;68(8):2927–33.
35-Maron DM, Ames BN. Revised methods for salmonella mutagenicity test. Mutat Res 1983;113(3-4):173-215.
36-Fazlibazzaz S, Izadyar AR. [Antimutagenic properties of fractions of herbal extract of norozak]. Iranian J Med Sci 2001;4:241-50. [In Persian]
37-Ames BN, Mccann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res 1975;31(6):347-64.
38- Mattocks AR. Chemistry and toxicology of pyrrolizidine alkaloids. Florida. Academic Press 1986:4019–27.
39-.Ballantyne B, Marrs T, Syversen T. General and Applied Toxicology. New York: Groves Dictionary INC; 1999.
40-Yazdi E. [Changes in the genetic material]. Tehran: ghalam publications; 1368. [In Persian]
41-Mortelmans K, Zeiger E. The Ames Salmonella/microsome  mutagenicity  assay.  Mutat Res  2000;455(1-2):29–60.
42-Gee P, Maron DM, Ames BN. Detection and classification of mutagens: a set of base-specific Salmonella tester strains. Proc Natl Acad Sci U S A 1994;91:11606–10.
43-Barnes W, Tuley E, Eisenstadt E. Base-sequence analysis of His+ revertants of the hisG46 missense mutation in Salmonella typhimurium. Environmental Mutagenesis 1982;4:297.
44-Willi J. The salmonella typhimutium reverse Mutation Assay. United State Environ Mental Protection Aganey. Health Effects Tests Guidelines 1996;219.
45-United States Environmental Protection Agency. Health Effects Tests Guidelines: OPPTS 870.5265, The Salmonella typhimurium Reverse Mutation Assay EPA712-C-96-219. Boston: United States Environmental Protection Agency; 1996.
46-Organization for Economic Cooperation and Development. OECD Guidelines for the Testing of Chemicals: Bacteria Reverse Mutation Test Guideline 471. City: OECD; 1997.
47-Rajurkar NS, Gaikwad K. Evaluation of phytochemicals, antioxidant activity and elemental content of Adiantum capillus veneris leaves. J Chem Pharma Res 2012;4(1):365-74.
48-Resende FA, Vilegas W, Dos Santos LC, Varanda EA. Mutagenicity of flavonoids assayed by bacterial reverse mutation (Ames) test. Molecules 2012;17(5):5255-68.
49-Bear WL, Teel RW. Effects of citrus flavonoids on the mutagenicity of heterocyclic amines and on cytochrome P450 1A2 activity. Anticancer Res 2000;20(5B):3609-14.